We monitored 133 high-risk allo-SCT recipients for 6 months after transplant for EBV reactivation by quantitative real-time PCR. Rituximab was given as pre-emptive therapy for viremia 41000 copies/mL. The 1-year cumulative incidence of EBV reactivation was 29.4% (95% confidence interval (CI): 18-40) in patients monitored due to initial high-risk characteristics (n = 93) and 31.8% (95% CI: 19.7-44) in those followed because of the development of refractory GVHD (n = 40). Overall response rate to Rituximab was 83%. Nine patients (9.6%) developed post-transplant lymphoproliferative disorder (PTLD) at a median of +62 days after SCT. Eight of them showed a concomitant CMV reactivation. Second SCT was the only risk factor associated with EBV infection and PTLD in multivariate analysis (hazard ratio (HR) 2.6 (95% CI: 1.1-6.4; P = 0.04) and HR 6.4 (95%CI: 1.3-32; P = 0.02)). The development of EBV reactivation was not associated with non-relapse mortality or OS (P = 0.97 and P = 0.84, respectively).
INTRODUCTION
Epstein-Barr virus-related post-transplant lymphoproliferative disorder (PTLD) is a serious complication after SCT with a mortality as high as 85%. 1 Major risk factors for PTLD include HLA disparity, graft T-cell depletion and administration of anti-thymocyte globulin (ATG) or other anti T-cell antibodies. 2, 3 PTLD is usually preceded by a preclinical phase characterized by rising EBV copies in peripheral blood which can be quantified by polymerase-chain reaction (PCR). Recent guidelines recommend monitoring EBV viral load in high-risk allo-SCT recipients, according to the mentioned predisposing factors. 4 The real incidence and prognosis of EBV disease are difficult to evaluate due to differences in the PCR methods used to test EBV DNA, the quantitative PCR thresholds for therapeutic intervention and the diversity of criteria for defining high-risk patients. 5 Efforts to improve immune responses by reducing immunosuppressive drugs remain as one of the cornerstones of management but are not applicable to patients with active GVHD; 6, 7 thus, eliminating B lymphocytes with the anti-CD20 monoclonal ab Rituximab is the most feasible treatment. 7 In the current study we compare the incidence and prognosis of EBV-related complications between patients with baseline highrisk characteristics for PTLD and patients affected by refractory GVHD, prospectively monitored for EBV DNAemia with early institution of Rituximab as pre-emptive therapy.
PATIENTS AND METHODS

Inclusion criteria and transplant characteristics
Between September 2006 and May 2013, 404 consecutive adult patients underwent allo-SCT at the Hospitals Sant Pau and Vall d'Hebrón in Barcelona with same protocols for transplantation, graft manipulation and GVHD prophylaxis. Ninety-three of them (23%) were considered 'initial high-risk recipients' for EBV-related complications. This group included patients with at least one of the following risk factors: HLA mismatched unrelated donor transplantation, cord blood transplantation and use of ATG or alemtuzumab in the conditioning. Forty additional patients (10%) were not considered high-risk at baseline, but developed steroid-refractory moderate-to-severe acute GVHD (SR-GVHD cohort) and had received salvage with inolimomab (n = 22), etanercept (n = 11), ATG (n = 4) sirolimus (n = 2) and mycophenolate mofetil (n = 1).
High-dose conditioning regimen was based on CY (120 mg/kg) and fractionated TBI (12 Gy) ) with targeted doses of oral BU, 10 mg/kg (or its equivalent i.v. dose) for myeloid malignancies or melphalan 140 mg/m 2 for lymphoid malignancies. In patients receiving mismatched unrelated donor SCT rabbit ATG was added (6-8 mg/kg total dose). For cord blood transplantation, the conditioning regimen was thiotepa (10 mg/kg), fludarabine (150 mg/m 2 total dose), BU (9.6 mg/kg i.v.) and rabbit ATG (6-8 mg/kg total dose). GVHD prophylaxis was CsA plus either mycophenolate mofetil or a short course MTX in most cases. In cord blood transplantation CsA was combined with prednisone (1 mg/kg/day on days +14 to +28) or mycophenolate mofetil 15 mg/kg/12 h. 8 All patients received the treatment in HEPA filtered air rooms. Supportive measures included antiviral, antifungal and trimethoprimsulfamethoxazole or nebulized pentamidine prophylaxis. Serial blood monitoring of galactomannan and CMV infection was done 1-3 times per week, as described elsewhere.
9,10 All participants gave written informed consent and the study was approved by the National and local ethics committees.
Diagnosis of acute GVHD (aGVHD) was based on clinical findings and confirmed with histological evaluation of affected organ(s). The overall grading followed the Przepiorka standard criteria.
11 Grades II-IV were treated with prednisone usually 2 mg/kg per day. Failure of corticosteroids was defined by overall aGVHD grade progression in the first 72 h of therapy or lack of improvement by day 7.
EBV load monitoring EBV DNAemia was measured weekly by plasma quantitative PCR. Monitoring started at the time of SCT in the group of 'initial high-risk patients' and after starting second line immunosuppressive therapy in 'SR-GVHD patients'. After the first 6 months, if no reactivation occurred, the screening for EBV was generally stopped. For a detailed description of the whole extraction process and PCR methods, see the Supplementary information online.
Definitions of EBV-related complications EBV reactivation was defined as any EBV PCR viral load in plasma above 1000 copies of DNA per mL. The diagnosis of proven/probable EBV-related PTLD was made according to the published data. 4 Proven EBV-PTLD was defined as the histologically diagnosed PTLD with symptoms and/or signs from the affected organ(s). In patients with pre-transplant diagnosis of lymphoma, positive in situ hybridization for EBV-encoded RNA was also required. Probable disease was defined as a typical clinical manifestation(s) of PTLD plus an EBV viral load above 1000 copies per mL, in the absence of other causative factors or established diseases. Day +100 post-SCT was used to separate early vs late PTLD. 4 
Management of EBV DNAemia and PTLD
Patients with EBV viral loads 41000 copies/mL on at least two consecutive occasions or those with one determination 42000 copies/mL were treated with Rituximab. Prior to each infusion patients were carefully examined for signs and symptoms of PTLD. In the absence of suggestive signs, Rituximab was administered at a dose of 375 mg/m 2 weekly until clearance of EBV reactivation (usually for a maximum of four infusions) and one more administration. A decrease of at least 20% of the daily dose of immunosuppressive drugs was attempted in the absence of active GVHD. When findings suggestive of PTLD were present, a computed tomography scan and a lymph node biopsy were obtained. Patients with PTLD received Rituximab (375 mg/m 2 ) at weekly intervals until the clearance of EBV viremia plus two additional infusions.
Response to treatment was classified according to standard definition. 13 The viral response was assessed based on the kinetics of EBV DNAemia decrease. In case of clinical failure or progression, treatment with chemotherapy, radiotherapy and/or DLIs were initiated.
End points and statistical analysis
The primary end point of the study was the incidence of EBV-related complications, including EBV reactivation and/or EBV-PTLD. Crosstabs and Student's t-test were used to identify baseline characteristics associated with this end point. Factors with P-valueo 0.1 in univariate analysis were entered into a multivariate proportional hazards Cox regression analysis. Pvalues o0.05 were considered statistically significant, and the hazard ratios (HRs) and their 95% confidence intervals (95% CIs) were calculated. OS and cumulative incidence of non-relapse mortality (NRM) were secondary end points. Survival end points were calculated from the infusion day to the date of death or last follow-up. OS was estimated by the Kaplan-Meier method and actuarial curves were compared with the log-rank test. [14] [15] [16] Statistical analyses were done with the SPSS version 19.0 (SPSS lic, Chicago, IL, USA). Cumulative incidence calculations were performed with NCSS 2004 (Kaysville, UT, USA). Table 1 summarizes the study population. We assessed 133 consecutive allo-SCT recipients considered at high risk for EBV disease. The first cohort (baseline) included 93 cases (70%), whereas the second (SR-GVHD cohort) included 40 (30%). For survivors, the median duration of EBV monitoring and follow-up were 180 days (15-557) and 604 (34-2204) days, respectively. EBV Reactivation and PTLD In the baseline cohort 22 patients (23.6%) developed EBV reactivation, for a +6-month and a +1-year cumulative incidence of 27.4% (95% CI: 22.2-32.6%) and 29.4% (95% CI: 18.4-40.5%), respectively. EBV DNAemia occurred at a median of +42 days Abbreviations: AL = acute leukemia; MDS = myelodysplastic syndrome; MM = HLA mismatch; MPN = myeloproliferative neoplasms; n = number; NA = not applicable; NHL = Non-Hodgkin lymphoproliferative disease; TCD = T cell depletion (including anti-thymocyte globulin or alemtuzumab); VUD = volunteer unrelated donor. a HLA compatibility was studied by high-resolution typing of HLA-A, B, C and DRB1 alleles and for DQB1 in case of unrelated donor. Acord blood unit must match at least four of six markers at HLA-A, -B and -DRB1 Advanced disease status was considered in patients with acute leukemia in ⩾ second (CR), myeloproliferative disease in ⩾ second chronic phase and in accelerate or blast phase, Hodgkin's disease in ⩾ third remission or with PR, follicular lymphoma ⩾ 3rd CR, large B-cell lymphoma or multiple myeloma ⩾ 2nd CR or PR and solid tumors. Patients with PR or persistent disease at transplantation (except for myeloma) were also considered as advanced disease status.
RESULTS
Patient characteristics
EBV-
Most cases occurred within the first 3 months after SCT with only five patients (22% of EBV reactivations) after day +100. The median EBV viral load at reactivation was 6636 copies/mL (range: 1011-210240) with 14 patients (15%) presenting values 410 000 copies/mL. PTLD was diagnosed in nine of the 93 cases (9.7%) of the baseline cohort, at a median of +62 days after SCT (range: 28-264). Additionally, four of the 271 patients (1.5%) who were not at high risk developed PTLD.
The 6 months and 1-year cumulative incidences of PTLD in the baseline cohort were 10.7% (95% CI: 7.1-14.3%) and 12.8% (95% CI: 8.7-17%). Late-onset PTLD occurred in two of the nine cases (days +109 and +264). Nine of the 13 patients had 410 000 copies/mL during follow-up after the diagnosis of PTLD was made.
EBV reactivation was found in six of the 40 patients (15%) monitored from the start of SR-GVHD, with the first positive PCR occurring at a median of 82 days (range: 25-298). The cumulative incidences of EBV reactivation at 6 and 12 months were 14.8% (95% CI: 7.9-21.7%) and 31.8% (95% CI: 19.7-43.9%). The median viral load at the reactivation was 1927 copies/mL (range: 1109-2274). Only one patient from this cohort had any viral load 410 000 copies/mL during follow-up and none developed probable or proven PTLD.
Risk factors for EBV infection and disease
Owing to the presence of two heterogeneous groups in our study, only patients in the baseline cohort (n = 93) were included in the risk factor analysis. The univariate and multivariate analyses of variables associated with the development of EBV reactivation and PTLD appear in Table 2 . In multivariate analysis, receiving a second SCT was the only significant variable associated with a higher risk of both EBV reactivation and PTLD (HR 2.6, (95% CI: 1.1-6.4, P = 0.04) and HR 6.4 (95% CI: 1.3-31.9; P = 0.02), respectively).
Management of EBV-related complications
Sixteen of the 22 patients with EBV infection in the baseline cohort were asymptomatic at the time of reactivation. Reduction of immunosuppression was feasible in 15 cases with 12 patients (75%) receiving Rituximab. Ten patients (83%) achieved a complete and sustained response after Rituximab, although three died later from other causes (bacterial infection (n = 1) and relapse of the primary disease (n = 2) 127-257 days after completing Rituximab therapy). In the remaining two (17%), the EBV load increased with progression to PTLD with one dying from this complication. The second patient responded to a donorlymphocyte infusion followed by CNS radiotherapy for cerebral involvement by PTLD, referring good performance status more than 5 years later. Three patients with uncomplicated EBV DNAemia did not receive Rituximab. The reasons were concomitant leukemia relapse and low viral loads (between 1000 and 2000 copies/mL) which gradually became negative after tapering immunosuppressive therapy. One high-risk patient not monitored due to an error received the first Rituximab dose after the diagnosis of PTLD. Retrospective analysis of stored serum samples showed a progressive rise in the EBV viral load from 1200 to 500 000 copies/mL during the previous 3 weeks. This patient achieved a CR after nine doses of Rituximab but died 3 months later due to multi-resistant Pseudomonas aeruginosa Pneumonia. Six of the 22 patients from the baseline cohort (28%) had a viral load 410 000 copies/mL when PTLD was diagnosed. Further details on the clinical presentation and outcome of patients diagnosed with PTLD are shown in Table 3 .
Among the 40 patients under EBV surveillance because of SR-GVHD, six (15%) had EBV DNA loads 41000 copies/mL. None of the 40 patients in this cohort developed PTLD and only one of the six patients (16%) received pre-emptive Rituximab (two doses) with clearance of EBV DNAemia. The remaining five patients were ineligible for pre-emptive therapy due to poor performance status, an all died from GVHD (n = 4) or disseminated listeriosis (n = 1).
Characteristics of patients affected by PTLD During the study period, 13 of the 404 allografted patients (3%) developed an EBV-PTLD. Four of these patients had not been included in the prospective monitoring due to lack of any of the risk factors and because of a registration error (n = 1). Details on Variables analyzed as time-dependent covariates. Gender and age of the recipient at SCT (more or less than 30 years), source of stem cells, CMV status, disease status at SCT, conditioning regimen, immunosuppressive schedule, EBMT risk score, comorbidity index and GVHD development were not associated with EBV-related events in the univariate analysis.
the clinical presentation and outcome of these 13 patients diagnosed with PTLD are shown in Table 3 .
PTLD was diagnosed at a median of day +70 (31-272) after SCT and only one occurred after day +180. Interestingly, none of the patients diagnosed with PTLD had received Rituximab therapy before transplant for their disease or sirolimus-based GVHD prophylaxis.
PTLD was biopsy-proven monomorphic diffuse large B-cell lymphoma in eight patients (62%) whereas five (38%) had probable disease. Eleven patients (85%) had lymphadenopathies at diagnosis. Tonsillar enlargement was evident in six cases (46%) and eight (62%) had abnormal liver function tests. Six patients developed PTLD in the setting of grade 2-4 aGVHD, 12 (92%) had concomitant CMV infection and five had BK polyomavirus-related hemorrhagic cystitis.
The most relevant laboratory finding was the sudden detection of a monoclonal gammopathy in six patients with PTLD: IgM (n = 4), IgG (n = 1) and biclonal (n = 1). Seven of the 13 patients (54%) with PTLD also had a sudden increase in peripheral blood B lymphocytes. The laboratory abnormalities developed in the week before the diagnosis of PTLD (two representative cases are shown in Figures 1 and 2 ) and were not observed after uncomplicated EBV reactivation. In addition, a clonal expansion of CD8-positive T cells was observed in two patients few weeks after therapy during concomitant regression of the PTLD. Outcome NRM occurred in 30 of the 93 patients (32%) of the baseline cohort, with an incidence of 34.5% at +1 year after SCT (95% CI: 29.1-40). The 1-year and 2-year probabilities of OS in this group was 60% (95% CI: 54.6-65.4) and 51% (95% CI: 45-57). Infectious complications were the main cause of death (46.1%), followed by relapse (23%), GVHD (aGVHD: 6 (15.4%), chronic GVHD: 1 (2.6%)) and primary graft failure (7.7%). PTLD was the primary cause of death in two patients (5%). The median time to death was 104 days (range: 15-620).
NRM occurred in 26 of the 40 patients (65%) of the SR-GVHD cohort, being the incidence of 67.4% at +1 year after SCT (95% CI: 59-75.7%). OS at 1 and 2 years were 28.2% (95% CI: 20.3-36%) and 21% (95% CI: 14.4-28.5%). Main cause of death was GVHD (89%).
Nine of the 13 patients (69%) diagnosed with PTLD (seven from the baseline cohort and two non-included in the routine EBV monitoring due to absence of high-risk features) died 4-445 days (median 19 days) after diagnosis. In four cases (44%) PTLD was the primary cause of death, whereas the other five responded to therapy but died from GVHD (n = 2), severe infection (n = 2) or primary graft failure (n = 1).
In the 133 patients monitored in whom EBV reactivation was analyzed as time-dependent covariate no impact was found on NRM and OS (P = 0.97 and 0.84, respectively).
DISCUSSION
We assessed the differences in the incidence and features of EBVrelated complications in two groups of patients, baseline cohort and SR-GVHD cohort, considered at high risk. To our knowledge, no previous studies focused on EBV monitoring due to SR-GVHD, 
12 (92%) BK-polyomavirus hemorrhagic cystitis, n (%) 5 (38%) Acute GVHD grade 2-4 at PTLD diagnosis, n (%) 6 (46%)
Abbreviations: DLBCL = diffuse large B-cell lymphoma; ECOG = Eastern Cooperative Oncology Group; n = number; PTLD = post-transplant lymphoproliferative disorder. despite this complication is highlighted as an important risk factor in most reports. 2, 4 Our results show that EBV reactivation is frequent in this group, with an incidence of around 30%, similar to that reported in other high-risk patients, [17] [18] [19] without differences compared with our 'baseline cohort' (29.4% vs 31.8%, NS). Remarkably, in the SR-GVHD cohort a relatively low viral load at the time of EBV reactivation was observed (median: 1927 vs 6636 copies/mL in the baseline cohort) tending to occur later after allo-SCT (82 days after the diagnosis of SR-GVHD).
In the SR-GVHD cohort due to their bad performance status Rituximab was administered in only 16% of the patients with EBV reactivation. This contrasts with the 75% of the cases treated in the baseline cohort. The first group had high short-term NRM (67.4% at +1 year after SCT) due to GVHD progression not being possible to evaluate the impact of pre-emptive Rituximab.
Receiving a second SCT was strongly associated with the risk of EBV-related complications, confirming previous observations. 2 No other classical risk factors were found such as recipient age, baseline disease or presence of acute or chronic GVHD. 20 CMV reactivation and BK poliomavirus hemorrhagic cystitis were frequently associated, likely reflecting severe immunosuppression. In contrast to a recent report, 17 we did not show differences in the risk of EBV disease between patients with and without CMV reactivation.
An interesting finding was that none of the 21 patients who received Rituximab in the 6 months before allo-SCT due to B-cell malignancies had EBV reactivation. Therefore, Rituximab during the conditioning regimen in high-risk patients deserves investigation, as well as sirolimus as GVHD prophylaxis, which could also prevent EBV disease. In this regard, EBV reactivation or PTLD were not observed in 14 patients from our series who received this agent. This small cohort does not allow firm conclusions, although this is in line with studies showing that sirolimus inhibits the growth of human EBV-transformed lymphocytes 'in vitro' and in xenotransplant models. 21 The current study found that despite close surveillance and pre-emptive Rituximab administration a number of patients in the baseline cohort developed a PTLD. This finding is consistent with prior studies reporting PTLD in 0-10% of transplant recipients.
18, [22] [23] [24] Even if the early introduction of Rituximab initially resolves this complication in most cases, a recent report by Uhlin et al. 25 showed that only 20% of patients with PTLD were alive 3 years later. In our study, nine of the 13 patients suffering from this complication died between 4 and 445 days after diagnosis.
Whether this low long-term survival is linked to long-lasting B lymphocyte depletion and hypogammaglobulinemia induced by Rituximab is difficult to establish. Petropoulou et al. 26 reported a 36-month cumulative incidence of bacterial, viral and fungal infections after Rituximab of 64%, 59% and 23%, respectively. These data indicate that Rituximab should be restricted to those patients at highest risk of PTLD and required a close monitoring to eventually start Ig replacement to limit infectious-related mortality.
In conclusion, this study reflects that EBV-related complications remain an important problem after allo-SCT. Close EBV viremia monitoring and early administration of Rituximab are necessary in the group of patients with high-risk factors, including those receiving intensive immunosuppression due to refractory GVHD. The current challenges are to select patients in whom prophylactic Rituximab should be administered before and/or after hematopoietic infusion and to investigate the methods for improving T-cell reconstitution after transplant. 
